<DOC>
	<DOCNO>NCT00106301</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability extend treatment FK228 patient metastatic renal cell carcinoma hormone refractory prostate cancer least demonstrated stable disease prior Fujisawa sponsor FK228 clinical trial .</brief_summary>
	<brief_title>Continuation Trial Evaluating Tolerability Activity FK228 Patients That Completed Prior Study With FK228</brief_title>
	<detailed_description>This Phase II , non-randomized , open-label , single arm , continuation trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Patient complete 6 cycle therapy prior Fujisawasponsored FK228 clinical trial ; Patient immediate past participation ( exceed 21 day Day 15 cycle 6 previous study ) prior Fujisawasponsored FK228 clinical trial ; Patient demonstrate stable disease , partial response complete response best overall response prior Fujisawasponsored FK228 clinical trial . Patient prior Fujisawasponsored FK228 clinical trial , leave trial receive alternative antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>FK228</keyword>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
</DOC>